Surging Prevalence Of Hereditary Angioedema Ignites Growth In The Market Emerges as a Core Driver of the Hereditary Angioedema Therapeutics Market in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Is the Expected CAGR for the Hereditary Angioedema Therapeutics Market Through 2025?
The market size for hereditary angioedema therapeutics has seen a swift expansion in recent times. The growth is forecasted to increase from $6.68 billion in 2024 to $7.77 billion in 2025 with a compound annual growth rate (CAGR) of 16.3%. Factors contributing to the growth in the historical period include enhanced diagnosis and consciousness, widened access to treatments, research and development undertakings, patient counseling and education, along with regulatory sanctions.

What's the Projected Size of the Global Hereditary Angioedema Therapeutics Market by 2029?
The market size for therapeutics related to hereditary angioedema is anticipated to expand significantly in the forthcoming years. The market value is forecasted to reach "$15.84 billion in 2029, with a compound annual growth rate (CAGR) of 19.5%. This upcoming growth can be associated with factors like progress in targeted treatments, expansion of the global market, advancements in gene therapy, the growing trend towards personalized medicine, and cooperative efforts in research and treatment. Noteworthy trends during the predicted period include initiatives for global access, research into health economic outcomes, strategies for early intervention, and focus on therapeutics for pediatric HAE.

View the full report here:
https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-therapeutics-global-market-report

Top Growth Drivers in the Hereditary Angioedema Therapeutics Industry: What's Accelerating the Market?
The hereditary angioedema market is slated to expand due to the increasing incidence of hereditary angioedema. This rare genetic condition is defined by recurring instances of intense swelling in the skin and mucous membranes caused by excessive fluid accumulation, technically referred to as EDEMA. The swelling may occur anywhere in the body, such as the hands, feet, face, intestines, and airways. For example, as per the data from the Rare Disease Advisor in June 2022, a health professionals' online resource company, globally around 1 in every 50,000 individuals are affected by hereditary angioedema. The prevalence estimates range from 1:10,000 to 1:150,000. In the US, visits to the emergency room due to HAE episodes total to 15,000 to 30,000 every year. Out of the total HAE cases, 5.8% were diagnosed within 0 to 6 months, while another 5.8% took more than 10 years to be diagnosed. Therefore, this rise in the incidence rate of hereditary angioedema is fueling the hereditary angioedema market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10810&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Hereditary Angioedema Therapeutics Market?
In the hereditary angioedema therapeutics market, a significant trend is the development of novel products by key companies. Noteworthy innovations are the ligand-conjugated (LICA) investigational antisense medicine and gene therapy being developed by these companies to maintain their market dominance. Specifically, Intellia Therapeutics, a clinical-stage biotech company operating out of the US, initiated an Investigational New Drug (IND), NTLA-2002, in March 2023. This drug, approved for hereditary angioedema treatment by the U.S Food and Drug Administration, paves the way for the company's ongoing Phase 1/2 trial to extend to the US as part of the global Phase 2 section. The therapeutic impact of a single dosage can permanently reduce plasma kallikrein protein activity and halt HAE attacks by inactivating the target gene, kallikrein B1 (KLKB1). The future potential of NTLA-2002 lies in in vivo genome editing.

What Are the Main Segments in the Hereditary Angioedema Therapeutics Market?
The hereditary angioedema therapeutics market covered in this report is segmented -

1) By Drug Class: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes
2) By Route of Administration: Intravenous, Subcutaneous, Oral
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Prophylaxis, On-demand

Subsegments:
1) By C1 Esterase Inhibitor: Plasma-Derived, Recombinant
2) By Selective Bradykinin B2 Receptor Antagonist: Icatibant
3) By Kallikrein Inhibitor: Ecallantide, Lanadelumab
4) By Other Drug Classes: Emerging Therapies

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10810&type=smp

Which Top Companies are Driving Growth in the Hereditary Angioedema Therapeutics Market?
Major companies operating in the hereditary angioedema therapeutics market include Sanofi S.A., Pharming Healthcare Inc., Attune Pharmaceuticals Inc., Adverum Biotechnologies Inc., Arrowhead Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., BioCryst Pharmaceuticals Inc., CSL Behring LLC, KalVista Pharmaceutical Inc., CENTOGENE N.V., GlaxoSmithKline plc., Eli Lilly and Company, Amgen Inc., AbbVie Inc., Incyte Corporation, BioMarin Pharmaceutical Inc., Dyax Corp., Salix Pharmaceuticals Inc., Pharvaris N.V., Innovent Biologics Inc., AstraZeneca plc, BeiGene Ltd., Jiangsu HenGrui Medicine Co. Ltd., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG ., Exelixis Inc., Lev Pharmaceuticals Inc., Kedrion Biopharma Inc., Pharos Pharmaceuticals Inc.

Which Regions Will Dominate the Hereditary Angioedema Therapeutics Market Through 2029?
North America was the largest region in the global hereditary angioedema therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hereditary angioedema therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10810

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.